№ files_lp_4_process_3_087188
File format: docx
Character count: 8229
File size: 153 KB
Year:
2026
Region / City:
Not specified
Subject:
Chemistry / Organic Chemistry
Document Type:
Laboratory guide / Experiment protocol
Institution:
Educational laboratory / School science department
Author:
Not specified
Target Audience:
Students and laboratory technicians
Experiment Level:
Advanced Higher / Secondary education
Chemicals Used:
Caffeine tablets, sodium carbonate, anhydrous sodium sulfate, ethyl ethanoate, ethanol
Equipment:
Beakers, conical flasks, Bunsen burner, hotplate, separating funnel, filter funnels, Buchner/Hirsch funnel, ice bath, balance, stirrers, pipettes
Procedure Steps:
Extraction, recrystallization, TLC identification
Safety Precautions:
Flammable solvents, respiratory irritants, eye and mucous membrane protection
Duration:
Multiple sessions possible, including overnight recrystallization
Reference Compounds:
Caffeine from tablets or other sources (e.g., tea)
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Title:
Preparation of Cyclohexene
Unit:
Unit 3 PPA 1
Subject Area:
Chemical Investigations
Topic:
Organic Chemistry
Experiment Focus:
Dehydration of cyclohexanol to form cyclohexene
Type of Document:
Laboratory experiment guide
Intended Audience:
Teachers and laboratory technicians
Chemicals Involved:
Cyclohexanol, 85% phosphoric acid, cyclohexene, sodium chloride solution, anhydrous calcium chloride, bromine solution
Apparatus:
Distillation setup with round-bottomed flasks, condenser, separating funnel, heating mantle, thermometer
Safety Requirements:
Use of eye protection and gloves; handling of corrosive, flammable and toxic substances
Procedure Elements:
Distillation, liquid-liquid separation, drying of organic layer, purification, yield calculation, unsaturation test
Assessment Component:
Calculation of percentage yield and confirmation of unsaturation
Year:
2014
Discipline:
Plant biology; biochemistry; molecular biology
Document type:
Classroom case study and assignment
Authors:
Brian Sullivan; Shuchismita Dutta
Affiliations:
Department of Plant and Microbial Biology, North Carolina State University, Raleigh NJ 27695; Institute for Quantitative Biomedicine, Rutgers University, Piscataway NJ 08854
Contact author:
[email protected]
Related publications:
Science, 2014, 345, 1181–1184; The New York Times, September 2014
Key topics:
Caffeine biosynthesis; N-methyltransferases; allelopathy; enzyme structure; Protein Data Bank
Referenced organisms:
Coffee plant; tea plant; cocoa plant; mate plant
Referenced resources:
DrugBank; RCSB Protein Data Bank
Educational context:
Pre-class preparation and in-class discussion
Year:
2013
Region / City:
United States
Topic:
Chemistry, Health
Document Type:
Article
Organization:
Not specified
Author:
Paul Cowan
Target Audience:
General public, students
Effective Period:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2023
Region / City:
Scotland
Topic:
Caffeine and Sugar Content in Beverages
Document Type:
Informational Guide
Organization:
Health Canada, World Health Organisation
Author:
Not specified
Target Audience:
Teenagers, General Public
Period of validity:
Not specified
Date of approval:
Not specified
Date of changes:
Not specified
Year:
2019
Region / city:
Australia, New Zealand
Theme:
Food safety
Document type:
Notification
Agency:
Food Standards Australia New Zealand (FSANZ)
Target audience:
WTO members, food industry
Period of validity:
From December 2019
Date of approval:
12 December 2019
Date of amendments:
N/A
Description:
The document informs about a temporary ban on the retail sale of foods containing high levels of caffeine in Australia and New Zealand, following health risks related to pure caffeine ingestion.
Year:
2026
Topic:
Nutrition / Health
Document Type:
Article compilation
Authors:
Multiple (unspecified)
Target Audience:
General public
Key Findings:
Conflicting conclusions on caffeine’s dehydrating effect; lethal dose information included
References:
Studies on coffee consumption and hydration
Keywords:
caffeine, dehydration, coffee, diuretic, fluid balance
Year:
2026
Region / City:
Not specified
Topic:
Human physiology, sleep research, caffeine metabolism
Document Type:
Research supplement
Institution:
University or clinical research laboratory (not specified)
Authors:
Not specified
Study Population:
Healthy adults aged 18–35, BMI 18–25, non-shift workers
Exclusion Criteria:
Extreme chronotype, high/low caffeine intake, poor sleep quality, substance use, recent transmeridian travel
Laboratory Assessments:
Sleep efficiency, apnea index, periodic leg movements, salivary caffeine concentration
Data Collection Period:
Not specified
Ethical Compliance:
Screening and toxicology assessments performed
Year:
2026
Institution:
SNAB / Exam Board
Centre Number:
12416
Candidate Number:
Provided in document
Subject:
Biology
Type:
Core practical assessment
Topic:
Effect of caffeine on heart rate
Organ / Teacher:
Teachers’ initials provided in document
Practical Number:
1
Skills Assessed:
Experimental technique, variable control, data collection, analysis and interpretation
Safety Considerations:
Use of stroboscope for photosensitive individuals, ethical treatment of Daphnia
Equipment:
Culture of Daphnia, cavity slides, pipettes, distilled water, caffeine tablets, cotton wool, standard glassware, stopclock, paper towels, microscope
Note:
Year
Document type:
Product Information
Organ / institution:
European Medicines Agency
Target audience:
Healthcare professionals, patients
Year:
2014
Region / city:
Australia
Topic:
Pharmaceutical product submission
Document type:
Application for listing
Organization / institution:
Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
AstraZeneca Pty Ltd
Target audience:
Health professionals, regulatory authorities
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
1 April 2014
Note:
Year
Organization / Institution:
NHS Scotland
Author:
Dr Laura Ryan, Dr John McAnaw, Mr Jim Miller
Target Audience:
Qualified health professionals within NHS Scotland
Changes History:
Eligibility age extended, new conditions added, clarifications made
Clinical Situation:
Acute uncomplicated urinary tract infection (UTI) in non-pregnant females aged 16 years and over.
Year:
2022
Region / City:
Australia
Topic:
Oncology / Hematology
Document Type:
Submission Report
Organ / Institution:
Therapeutic Goods Administration (TGA), Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
Celgene Pty Limited
Target Audience:
Healthcare professionals, regulatory authorities
Validity Period:
Ongoing
Approval Date:
8 April 2022
Amendment Date:
Not specified
Year:
2017
Region / city:
Australia
Topic:
Treatment of moderate to severe plaque psoriasis
Document type:
Resubmission for PBS listing
Authority:
Therapeutic Goods Administration (TGA)
Author:
Celgene Pty Ltd
Target audience:
Healthcare professionals, dermatologists, general physicians
Period of validity:
Ongoing
Approval date:
2017
Date of amendments:
2017
Year:
2026
Region / City:
Europe
Subject:
Product Information
Document Type:
Summary of Product Characteristics
Organization / Institution:
European Medicines Agency
Author:
European Medicines Agency
Target Audience:
Healthcare professionals
Period of Validity:
Ongoing
Approval Date:
2026
Date of Changes:
2026
Year:
2025
Region / City:
England
Topic:
Emergency contraception
Document type:
Patient Group Direction (PGD)
Organization / Institution:
NHS England
Author:
Dr Cindy Farmer, Michelle Jenkins, Vicky Garner, Gail Rowley, Julia Hogan, Kate Devonport, Chetna Parmar, Helen Donovan, Carmel Lloyd, Clare Livingstone, Kirsty Armstrong, Dipti Patel, Emma Anderson, Dr Kathy French, Dr Sarah Pillai, Alison Crompton, Andrea Smith, Lisa Knight, Bola Sotubo, Tracy Rogers, Sandra Wolper, Jo Jenkins
Target audience:
Pharmacists, Pharmacy Technicians
Effective period:
June 2025 - February 2026
Approval date:
November 2022
Review date:
September 2025
Expiry date:
February 28, 2026
Year:
2023
Region / city:
Europe
Theme:
Pharmaceutical, HIV Treatment
Document Type:
Summary of Product Characteristics
Organization / Institution:
European Medicines Agency (EMA)
Author:
European Medicines Agency
Target audience:
Healthcare professionals, doctors
Validity period:
Not specified
Approval date:
Not specified
Amendment date:
Not specified
Year:
2025
Author:
Bahá’u’lláh
Religious Tradition:
Bahá’í Faith
Genre:
Sacred scripture
Form:
Tablets and devotional texts
Primary Themes:
Revelation, divine love, steadfastness, martyrdom, spiritual transformation
Named Individuals:
Muḥammad-‘Alí
Liturgical Element:
Tablet of visitation
Language Style:
Devotional and exhortatory prose
Intended Audience:
Believers and followers of the Cause of God
Historical Context:
Successive divine dispensations and fulfillment of prophetic promises
Name of the medicinal product:
Miraba-S Tablets
Active substances:
Mirabegron (Extended-Release) 25 mg; Solifenacin succinate 5 mg
Pharmaceutical form:
Film coated tablet
Description:
Yellow coloured, round, biconvex, film coated tablet
Therapeutic indications:
Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency
Posology:
One tablet daily; may increase to two tablets daily after 4 to 8 weeks based on efficacy and tolerability
Dose adjustments:
Maximum once daily in severe renal impairment (CLcr 15–29 mL/min or eGFR 15–29 mL/min/1.73 m2) or moderate hepatic impairment (Child-Pugh Class B); not recommended in ESRD or severe hepatic impairment
Method of administration:
Swallowed whole with water, with or without food; not chewed, divided, or crushed
Contraindications:
Hypersensitivity to mirabegron, solifenacin succinate, or any excipients
Special warnings and precautions:
Risk of increased blood pressure, urinary retention, angioedema, and interactions with CYP2D6 substrates
Drug interactions:
CYP2D6 substrates (e.g., metoprolol, desipramine, thioridazine, flecainide, propafenone); digoxin; warfarin
Fertility:
No human data available; no treatment-related effects observed in animals
Pregnancy:
No adequate studies in pregnant women
Lactation:
No information on presence in human milk or effects on breastfed child
Effects on ability to drive and use machines:
Mirabegron has negligible influence; solifenacin may cause blurred vision, somnolence, and fatigue
Undesirable effects:
Dry mouth, urinary tract infection, constipation, tachycardia, hypertension, urinary retention, angioedema
Reporting of suspected adverse reactions:
Healthcare professionals advised to report adverse reactions
Year:
2021
Region / City:
Global
Topic:
Medicine/Pharmaceuticals
Document Type:
Pharmaceutical Product Information
Organization:
N/A
Author:
N/A
Target Audience:
Healthcare Professionals
Effective Period:
N/A
Approval Date:
N/A
Amendment Date:
N/A